Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Boosting of Osimertinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with EGFR-mutated NSCLC receiving standard treatment with osimertinib for at least 2 months (steady state), without any signs of disease progression, or during treatment beyond progression, if treatment continuation is expected for multiple months. After anticipated EMA approval of osimertinib adjuvant therapy, patients on adjuvant osimertinib treatment may also participate on the following conditions; If they are receiving standard treatment with osimertinib for at least 2 months (steady state), and if treatment will be continued for a longer period than necessary for participation in the OSIBOOST trial.~* Age ≥ 18 years~* WHO performance status ≤ 2.~* Able and willing to give written informed consent.~* Able and willing to undergo blood sampling for pharmacokinetic analysis.~* Patients with osimertinib plasma trough concentration below 195 ng/mL. Plasma trough concentration of osimertinib will be determined in another study (METC MUMC: 2018-0800).~Exclusion Criteria:~* Any concurrent medication that is known to strongly inhibit or induce CYP3A4.~* Any concurrent medication that is primarily metabolized by CYP3A4 with a narrow therapeutic window.~* Impairment of gastrointestinal function that may alter the absorption of osimertinib or cobicistat (e.g. ulcerative disease, uncontrolled nausea or vomiting, malabsorption syndrome, small bowel resection).~* Refusing to refrain from consuming CYP3A4 influencing products, e.g. grapefruit(juice), St. John's wort.~* Pregnancy or breast feeding~* Child-Pugh score class C, chronic liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cobicistat (Type: EXPERIMENTAL): Cobicistat will serve as experimental drugs, and will be added to the regular treatment with osimertinib. Combination-treatment will be started at 150 milligram cobicistat, and can be increased to a maximum daily dose of 600 milligram cobicistat (four times 150 milligram).

Based on this trial design, predict the completion outcome and termination type (if applicable).